Quantcast

Latest Rosetta Genomics Ltd. Stories

2011-07-06 07:01:00

PHILADELPHIA and REHOVOT, Israel, July 6, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced the effectiveness of a one-for-four reverse stock split of its share capital. The reverse stock split, which was previously approved by the Company's Board of Directors, was approved by its shareholders at the 2011 Annual General Meeting of Shareholders of the Company held earlier today. The...

2011-05-09 07:33:00

PHILADELPHIA and REHOVOT, Israel, May 9, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,943,745, which is related to human hsa-miR-497 and its variants and covers the composition of matter. Human hsa-miR-497 is an important component of the Company's miRview(TM) mets and mets2 diagnostic tests for the accurate identification of the tissue of origin in Cancers of Unknown Primary...

2011-04-12 06:50:00

PHILADELPHIA and REHOVOT, Israel, April 12, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG) today announced that the Company's Board of Directors has appointed Director Brian A. Markison, former Chairman and Chief Executive Officer of King Pharmaceuticals, as Rosetta's new Board Chairman, as current chairman, Yoav Z. Chelouche, has resigned from the Company's Board and from his role as its Chairman effective today. Mr. Chelouche continues to serve as the Chairman of Rosetta...

2009-04-13 06:00:00

MicroRNA-based Molecular Diagnostics to Mark Prometheus' Entry into Oncology Market; Rosetta to Receive Milestones and Research and Development Funding plus Future Royalties SAN DIEGO, PHILADELPHIA and REHOVOT, Israel, April 13 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Rosetta Genomics Ltd. (Nasdaq: ROSG), an innovative molecular diagnostic company, today announced the execution of a license and collaboration agreement under which...

2009-02-12 07:30:00

PHILADELPHIA, and REHOVOT Israel, February 12 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG) reported today the first ever in-vivo efficacy data for a systemic microRNA-based cancer therapeutic. The animal-model study demonstrated a marked suppression of a microRNA that was found to be over expressed in human hepato-cellular carcinoma (HCC), and a significant two-fold reduction of tumor mass. These data are being presented at the Keystone Symposium, Therapeutic Modulation...

2009-01-16 07:30:00

PHILADELPHIA, Pennsylvania and REHOVOT Israel, January 16 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG) and collaborators, today unveiled initial data relating to the company's colorectal cancer screening diagnostics test, miRscreen(TM) colon, which is based on a simple blood draw, and is expected to be released next year. The company's scientists and collaborators have identified microRNA biomarkers in serum, which have the potential to accurately differentiate colorectal...

2009-01-08 07:30:00

REHOVOT, Israel and JERSEY CITY, New Jersey, January 8 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today it has signed an exclusive distribution agreement with Teva Pharmaceutical Industries Ltd. Under the terms of the agreement Teva will offer Rosetta Genomics' miRview(TM) tests in Israel and Turkey. The terms of the deal were not disclosed. "This is yet another important step in Rosetta...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related